Quick Answer
Denali Therapeutics Inc. reported Net Income Loss of -$512.54 million for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -21.2% in Net Income Loss from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Net Income Loss has declined by 491.5%.
- Historical annual values: Fiscal year 2025: -$512.54 million | Fiscal year 2024: -$422.77 million | Fiscal year 2023: -$145.22 million | Fiscal year 2022: -$325.99 million | Fiscal year 2021: -$290.58 million | Fiscal year 2020: $71.14 million | Fiscal year 2019: -$197.61 million | Fiscal year 2018: -$36.24 million | Fiscal year 2017: -$88.19 million | Fiscal year 2016: -$86.65 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: